Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis

Christian Thiede, Christine Steudel, Brigitte Mohr, +9

Blood

Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions

Valentin Goede, Kirsten Fischer, Raymonde Busch, +20

New England Journal of Medicine

Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML)

Christian Thiede, Sina Koch, Eva Creutzig, +4

Blood

Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma

Ajai Chari, Dan T. Vogl, Maria Gavriatopoulou, +49

New England Journal of Medicine

Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial

Christoph Röllig, Hubert Serve, Andreas Hüttmann, +41

The Lancet Oncology

Sorafenib Versus PlaceboHematological MalignancyOncologyMixed-phenotype Acute LeukemiaHematology +7

Advanced Glycation End Product-Induced Activation of NF-κB is Suppressed by α-Lipoic Acid in Cultured Endothelial Cells

Angelika Bierhaus, Shlomit Chevion, Mordechai Chevion, +10

Diabetes

P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate

Thomas Illmer, Markus Schaich, Uwe Platzbecker, +7

Leukemia

Hematological MalignancyMedicineMixed-phenotype Acute LeukemiaPharmacologyResistance Mechanism +8

Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing medium

Malte von Bonin, Friedrich Stölzel, Anja Goedecke, +12

Bone Marrow Transplantation

Platelet Lysate-containing MediumThrombosisThird-party MscRefractory Acute GvhdThrombopoiesis +5

First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia

Barbara Eichhorst, Carsten Utoft Niemann, Arnon P. Kater, +47

New England Journal of Medicine

MDR1 gene polymorphisms affect therapy outcome in acute myeloid leukemia patients.

Thomas Illmer, Ulrich S. Schuler, Christian Thiede, +7

PubMed

Mixed-phenotype Acute LeukemiaGeneticsImmunologyHuman PolymorphismPathology +16